BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23373648)

  • 1. Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.
    Negi A; Ramarao P; Kumar R
    Mini Rev Med Chem; 2013 Apr; 13(5):653-81. PubMed ID: 23373648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
    Jin M; Wang J; Buck E; Mulvihill MJ
    Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
    Zimmermann K; Wittman MD; Saulnier MG; Velaparthi U; Sang X; Frennesson DB; Struzynski C; Seitz SP; He L; Carboni JM; Li A; Greer AF; Gottardis M; Attar RM; Yang Z; Balimane P; Discenza LN; Lee FY; Sinz M; Kim S; Vyas D
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1744-8. PubMed ID: 20153189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting insulin-like growth factor axis in hepatocellular carcinoma.
    Wu J; Zhu AX
    J Hematol Oncol; 2011 Jul; 4():30. PubMed ID: 21729319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats.
    Wang Y; Malkowski M; Hailey J; Turek-Etienne T; Tripodi T; Pachter JA
    J Exp Ther Oncol; 2004 Jul; 4(2):111-9. PubMed ID: 15500006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
    Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
    Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells.
    Zovko A; Novak M; Hååg P; Kovalerchick D; Holmlund T; Färnegårdh K; Ilan M; Carmeli S; Lewensohn R; Viktorsson K
    Oncotarget; 2016 Aug; 7(31):50258-50276. PubMed ID: 27384680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.
    Miller LM; Mayer SC; Berger DM; Boschelli DH; Boschelli F; Di L; Du X; Dutia M; Floyd MB; Johnson M; Kenny CH; Krishnamurthy G; Moy F; Petusky S; Tkach D; Torres N; Wu B; Xu W
    Bioorg Med Chem Lett; 2009 Jan; 19(1):62-6. PubMed ID: 19041240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
    van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between IGF-1R and other tumor promoting pathways.
    Liu C; Zhang Z; Tang H; Jiang Z; You L; Liao Y
    Curr Pharm Des; 2014; 20(17):2912-21. PubMed ID: 23944361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy of the insulin-like growth factor-1 receptor in cancer.
    Paz K; Hadari YR
    Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.
    Mayer SC; Banker AL; Boschelli F; Di L; Johnson M; Kenny CH; Krishnamurthy G; Kutterer K; Moy F; Petusky S; Ravi M; Tkach D; Tsou HR; Xu W
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3641-5. PubMed ID: 18501599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
    Buck E; Mulvihill M
    Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.
    Xue M; Cao X; Zhong Y; Kuang D; Liu X; Zhao Z; Li H
    Curr Pharm Des; 2012; 18(20):2901-13. PubMed ID: 22571659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
    Buchanan JL; Newcomb JR; Carney DP; Chaffee SC; Chai L; Cupples R; Epstein LF; Gallant P; Gu Y; Harmange JC; Hodge K; Houk BE; Huang X; Jona J; Joseph S; Jun HT; Kumar R; Li C; Lu J; Menges T; Morrison MJ; Novak PM; van der Plas S; Radinsky R; Rose PE; Sawant S; Sun JR; Surapaneni S; Turci SM; Xu K; Yanez E; Zhao H; Zhu X
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2394-9. PubMed ID: 21414779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
    Tandon R; Kapoor S; Vali S; Senthil V; Nithya D; Venkataramanan R; Sharma A; Talwadkar A; Ray A; Bhatnagar PK; Dastidar SG
    Eur J Pharmacol; 2011 Sep; 667(1-3):56-65. PubMed ID: 21640718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor.
    Anastassiadis T; Duong-Ly KC; Deacon SW; Lafontant A; Ma H; Devarajan K; Dunbrack RL; Wu J; Peterson JR
    J Biol Chem; 2013 Sep; 288(39):28068-77. PubMed ID: 23935097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.